JPH04278460A - Method for controlling examination result of urine sediment, control marker particle and preparation thereof - Google Patents

Method for controlling examination result of urine sediment, control marker particle and preparation thereof

Info

Publication number
JPH04278460A
JPH04278460A JP6383791A JP6383791A JPH04278460A JP H04278460 A JPH04278460 A JP H04278460A JP 6383791 A JP6383791 A JP 6383791A JP 6383791 A JP6383791 A JP 6383791A JP H04278460 A JPH04278460 A JP H04278460A
Authority
JP
Japan
Prior art keywords
particles
marker
urine
particle
marker particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6383791A
Other languages
Japanese (ja)
Other versions
JP2913219B2 (en
Inventor
Hideo Araki
秀夫 荒木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIMA KENKYUSHO KK
Original Assignee
SHIMA KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHIMA KENKYUSHO KK filed Critical SHIMA KENKYUSHO KK
Priority to JP3063837A priority Critical patent/JP2913219B2/en
Publication of JPH04278460A publication Critical patent/JPH04278460A/en
Application granted granted Critical
Publication of JP2913219B2 publication Critical patent/JP2913219B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PURPOSE:To enhance the reproducibility of an examination result and to standardize said examination result, in the microscopic examination of a urine sediment, by eliminating the individual difference between urine specimens, the difference between measuring persons and the difference between installations. CONSTITUTION:The objective particles such as erythrocytes present in urine and marker particles discriminable under microscopic observation are added to urine to be centrifugally separated and the objective particles and marker particles in the obtained urine sediment are counted to correct the number of the objective particles on the basis of the recovery of the marker particles. The marker particles have a particle size of l-20mum and specific gravity of 1.040 or more and are different from the objective particles in a particle size or a hue under microscopic observation. Fixed erythrocytes are stained with 3,3'-diaminobenzidine and hydrogen peroxide to obtain brown marker particles.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は尿沈渣検査成績管理方法
、管理用マーカー粒子及びその製法にかかるものである
[Field of Industrial Application] The present invention relates to a method for managing urine sediment test results, marker particles for management, and a method for producing the same.

【0002】0002

【従来の技術】尿中には、毛細管出血による赤血球、血
管外遊走による白血球、腎臓や尿生殖器官に並ぶ上皮細
胞、ある状況下で腎尿細管において形成される円柱、そ
してしばしば局所感染や全身感染による細菌、真菌、原
虫、寄生虫等の微生物等の有形成分が含まれる。又、尿
には腎不全の場合、化学成分、医薬品や遊離の脂肪から
なる結晶が含まれることがある。
BACKGROUND OF THE INVENTION Urine contains red blood cells due to capillary hemorrhage, white blood cells due to extravasation, epithelial cells lining the kidneys and genitourinary organs, casts that form in the renal tubules under certain circumstances, and often local infections and systemic Contains tangible components such as microorganisms such as bacteria, fungi, protozoa, and parasites caused by infection. Additionally, in cases of renal failure, urine may contain crystals consisting of chemical components, pharmaceuticals, and free fats.

【0003】従って、尿の顕微鏡検査によって、その存
在の有無、形態及び数が臨床的に意味を持つこれらの成
分、及び他の成分の濃度を知ることができ、患者の病状
に対し明確な判断を与えることができることから、尿沈
渣の顕微鏡検査は世界的に広く普及している。
[0003] Therefore, by microscopic examination of urine, it is possible to know the concentration of these components and other components whose presence, absence, shape, and number are clinically significant, and it is possible to make clear judgments about the patient's medical condition. Microscopic examination of urine sediment is widely used worldwide because of its ability to provide

【0004】従来から行われている尿沈渣顕微鏡検査法
The conventional urinary sediment microscopy method is

【図1】に示すように、採尿カップ1の中の尿検体2を
よく混和して成分を均一にしてからスピッツ管3の10
mlの標線4まで正確に採取し、遠心分離機5により1
500r.p.m.5分間遠心分離し、上清をデカント
又は吸引により除去して200μl(濃縮率50倍)の
尿沈渣6を得る。次いで、尿沈渣6を均一に懸濁して約
15μlをスライドグラス7に移し、カバーグラス8を
かけて顕微鏡9のステージにセットし、倍率400倍で
粒子の形態を観察し、分類・計数すると共に記録用紙に
結果を手で記録している。
As shown in FIG. 1, mix the urine sample 2 in the urine collection cup 1 well to make the components uniform, and then
Accurately sample up to the ml mark line 4 and use a centrifuge 5 to
500r. p. m. Centrifuge for 5 minutes and remove the supernatant by decanting or aspiration to obtain 200 μl (50 times concentration) of urine sediment 6. Next, the urine sediment 6 was uniformly suspended and about 15 μl was transferred to a slide glass 7, covered with a cover glass 8 and set on the stage of a microscope 9, and the morphology of the particles was observed at a magnification of 400 times, and the particles were classified and counted. Results are recorded manually on recording paper.

【0005】しかしながら、尿検体2は尿沈渣量におい
て個体差が大きく、非常に薄くて尿沈渣量が僅かしかな
いものから、粘液成分を多量に含み尿沈渣量が200μ
l(尿10ml当り)を大幅に超える場合がある。又、
尿沈渣量の多い尿検体2は混和が不十分になりやすい。
However, there are large individual differences in the amount of urine sediment in urine specimen 2, ranging from very thin urine sediment with only a small amount to those containing a large amount of mucus and having a urine sediment amount of 200μ.
1 (per 10 ml of urine). or,
Urine sample 2 with a large amount of urine sediment tends to be insufficiently mixed.

【0006】又、操作法においても検査施設により使用
するスピッツ管3にメーカー差があり、遠心分離におい
ても回転数、遠心時間は統一されてはいても使用する遠
心分離機5により負荷される遠心力は夫々異なり、尿中
の各粒子の回収率も検査施設により異なってしまう。
[0006] Also, in terms of operating methods, there are differences in the manufacturers of the Spitz tubes 3 used depending on the testing facility, and even in centrifugation, although the rotation speed and centrifugation time are standardized, the centrifugation load imposed by the centrifuge 5 used is The forces are different, and the recovery rate of each particle in urine also varies between testing facilities.

【0007】更に、上清を除去する際に吸引除去により
行えば尿沈渣量を正確に200μlとすることは可能で
あるが、この方法では手間と時間がかかることから、検
体数の多い検査施設ではデカントで行うのが一般的であ
り、そのため尿沈渣量が個体差を大きく反映してしまい
、200μlよりも少なかったり、200μlよりも多
くなったりして、濃縮率が大きく変動してしまう。
Furthermore, if the supernatant is removed by suction, it is possible to accurately reduce the amount of urine sediment to 200 μl, but this method is laborious and time-consuming, so it is not suitable for testing facilities that handle a large number of specimens. It is common to perform this by decantation, and as a result, the amount of urine sediment largely reflects individual differences, and may be less than 200 μl or greater than 200 μl, resulting in large fluctuations in the concentration ratio.

【0008】又更に、尿沈渣6をスライドグラス7に移
す場合、
Furthermore, when transferring the urine sediment 6 to the slide glass 7,

【図1】に示すようにスポイト10で尿沈渣6を懸濁し
15μl採取すればよいが、手間とコストがかかるので
、検体数の多い検査施設ではスポイト10を使用せず、
スピッツ管3を軽く振って尿沈渣6の混和を行い、スピ
ッツ管3を逆さにし、スライドグラス7上にたたきつけ
るようにして尿沈渣6を一滴採取しているところが多い
。しかし、このようなたたきつけ法では、尿沈渣6の懸
濁が不十分となったり、滴下する容量も基準量である1
5μlよりも少なくなったり、多くなったりしてばらつ
いてしまう。
As shown in FIG. 1, it is sufficient to suspend the urine sediment 6 with a dropper 10 and collect 15 μl, but this is time-consuming and costly, so the dropper 10 is not used in testing facilities that handle a large number of specimens.
In many cases, the spitz tube 3 is gently shaken to mix the urine sediment 6, and the spitz tube 3 is turned upside down and tapped onto a slide glass 7 to collect a drop of the urine sediment 6. However, with such a tapping method, the suspension of the urine sediment 6 may be insufficient, and the volume to be dropped may not be the standard amount 1.
The amount varies, sometimes being less than 5 μl and sometimes more than 5 μl.

【0009】このように尿は、簡単に得られ、これらか
ら得られる診断情報が多い反面、含有成分が変性し易く
、何がどれだけ含まれているかの予測がつきにくく、判
定に検体の個体差、検査施設間差、検査担当者間差等が
入り易いことが難点とされている。そのため尿沈渣の標
準化の必要性が認識されている。
[0009] As described above, although urine is easily obtained and there is a lot of diagnostic information that can be obtained from it, the components contained in it are easily denatured and it is difficult to predict what and how much it contains. Difficulties include the possibility of differences, differences between testing facilities, differences between testing personnel, etc. Therefore, the need for standardization of urine sediment is recognized.

【0010】従来は尿沈渣の標準化の方法は定められて
おらず、精度管理を目的として尿沈渣用コントロール尿
を使用する方法が提案されている。すなわち、健常人血
液をNaCl加リン酸緩衝液(PBS)で洗浄し、2.
5%グルタルアルデヒドで固定した赤血球と、前記血液
から分取した白血球を同様にグルタルアルデヒドで固定
した白血球とを、正常尿をプールしてホルマリンを0.
5%濃度に加え、4℃で一夜以上放置した後沈殿物を除
き、アジ化ナトリウムを加えて得たプール尿に一定濃度
となるよう加えてなるコントロール尿を、日常の検査の
際に同時に赤血球及び白血球数を検査し検査成績を管理
しようとするものである。(衛生検査、39巻、1号、
1990、55〜61)
[0010] Conventionally, there has been no standardization method for urinary sediment, and a method of using control urine for urinary sediment has been proposed for the purpose of quality control. That is, healthy human blood was washed with phosphate buffered saline (PBS) containing NaCl, and 2.
Red blood cells fixed with 5% glutaraldehyde and white blood cells collected from the blood and fixed with glutaraldehyde in the same manner were pooled together with normal urine and treated with 0.0% formalin.
In addition to the 5% concentration, a control urine obtained by adding sodium azide to the pooled urine obtained after leaving it at 4°C overnight, removing the precipitate, and adding sodium azide to a constant concentration was used to simultaneously collect red blood cells during routine tests. The purpose is to test the number of white blood cells and to manage the test results. (Hygiene Inspection, Volume 39, No. 1,
1990, 55-61)

【0011】[0011]

【発明が解決しようとする課題】しかしながら、かかる
コントロール尿を用いる管理方法では、同一検査施設内
において検査担当者間差をなくし再現性を高める手段と
しては有効であるが、尿検体の個体差すなわち尿沈渣量
の多少によるばらつきは是正できない。
[Problems to be Solved by the Invention] However, although this control method using control urine is effective as a means of eliminating differences between testers and improving reproducibility within the same testing facility, it is difficult to avoid individual differences in urine samples. Variations in the amount of urine sediment cannot be corrected.

【0012】又、前記コントロール尿を使用し、全国の
58検査施設において各検査施設のルーチン法で検査し
たところ、固定赤血球33個/μl(1視野当りの理論
値12.1個/HPF)の調整表示値に対し、1視野当
り2.0〜52.7個、平均18.8個、CV59.6
%という成績が得られ、施設間変動が極めて大きく、標
準化の必要性が再認識されている(医学検査、40巻、
1号、1991、75〜79)。
[0012] Furthermore, when the control urine was tested at 58 testing facilities across the country according to their own routine methods, the number of fixed red blood cells/μl (theoretical value 12.1 cells/HPF per field of view) was 33. Compared to the adjusted display value, 2.0 to 52.7 pieces per field of view, average 18.8 pieces, CV59.6
%, and the variation between facilities is extremely large, reaffirming the need for standardization (Medical Examination, Vol. 40,
1, 1991, 75-79).

【0013】従って、各検査施設は前記コントロール尿
を用いた検査成績が表示値の33個/μl(12.1個
/HPF)となるよう検査法の改善に取り組まなければ
ならないが、前述のように変動の要因の多い尿沈渣の検
査成績の精度を高めるためには、手間と時間をかけざる
を得ず、高コスト化すると共に多数検体の処理能力に限
界を生じてしまう。
[0013] Therefore, each testing facility must work on improving the test method so that the test result using the control urine is the indicated value of 33 cells/μl (12.1 cells/HPF), but as mentioned above, In order to improve the accuracy of test results for urine sediment, which has many variables, it is necessary to spend time and effort, which increases costs and limits the ability to process a large number of samples.

【0014】[0014]

【課題を解決するための手段】本発明は上述の従来の課
題を解決するためになしたもので、尿にマーカー粒子を
加えて遠心分離し、得られる尿沈渣中の目的粒子及びマ
ーカー粒子を計数し、マーカー粒子の回収率により目的
粒子の数を補正することを特徴とする尿沈渣検査成績管
理方法にかかるものである。
[Means for Solving the Problems] The present invention was made to solve the above-mentioned conventional problems, and involves adding marker particles to urine and centrifuging the mixture to separate target particles and marker particles in the urine sediment obtained. The present invention relates to a urine sediment test result management method characterized by counting the target particles and correcting the number of target particles based on the recovery rate of marker particles.

【0015】ここにおいて、前記補正の方法は以下の3
通りである。
[0015] Here, the correction method is as follows:
That's right.

【0016】(計数された目的粒子の数)×(理論的回
収マーカー粒子数÷計数されたマーカー粒子の数)・・
・(式1)
(Number of target particles counted)×(Theoretical number of recovered marker particles ÷ Number of marker particles counted)...
・(Formula 1)

【0017】(計数された目的粒子の数)×(実験的回
収マーカー粒子数÷計数されたマーカー粒子の数)・・
・(式2)
(Number of target particles counted) x (Number of experimentally recovered marker particles ÷ Number of marker particles counted)...
・(Formula 2)

【0018】(計数された目的粒子の数÷計数されたマ
ーカー粒子の数)×(添加されたマーカー粒子の尿中濃
度)・・・(式3)
(Number of target particles counted ÷ Number of marker particles counted) × (Urine concentration of added marker particles) (Formula 3)

【0019】更に、尿にマーカー粒子を加えて遠心分離
し、得られる尿沈渣中の目的粒子及びマーカー粒子を計
数し、マーカー粒子に対する目的粒子の比率により尿検
体をランク分けすることも可能である。以上の補正の方
法は複数併用してもよい。
Furthermore, it is also possible to add marker particles to urine and centrifuge it, count the target particles and marker particles in the urine sediment obtained, and rank the urine sample based on the ratio of target particles to marker particles. . The above correction methods may be used in combination.

【0020】以上の尿沈渣検査成績管理方法に使用する
マーカー粒子としての発明は、粒子径が1〜20μm、
比重が1.040以上のマーカー粒子である。好ましく
は粒子径2〜10μm、比重1.05〜1.20のマー
カー粒子。又、マーカー粒子の粒子径は尿沈渣中の目的
粒子と粒子径を異にすることが好ましい。ここで、目的
粒子とは、尿沈渣中に認められる粒子のうちの一つ又は
二つ以上をいう。例えば、赤血球、白血球、組織球等の
血球成分、へん平、移行、尿細管(小円形)、脂肪含有
細胞、封入体細胞、多核巨細胞、異型細胞等の上皮細胞
、硝子、顆粒、ろう様、赤血球、白血球、血液、上皮、
脂肪、類円柱等の円柱、シュウ酸カルシウム、リン酸ア
ンモニウムマグネシウム、リン酸カルシウム、炭酸カル
シウム、尿酸アンモニウム、尿酸、ビリルビン等の結晶
、細菌、酵母様真菌、脂肪球、無晶性塩類等その他の粒
子がある。
[0020] The invention as marker particles used in the above urine sediment test result management method has particle diameters of 1 to 20 μm,
The marker particles have a specific gravity of 1.040 or more. Marker particles preferably have a particle diameter of 2 to 10 μm and a specific gravity of 1.05 to 1.20. Further, it is preferable that the particle size of the marker particles is different from that of the target particles in the urine sediment. Here, the term "target particles" refers to one or more particles found in urine sediment. For example, blood cell components such as red blood cells, white blood cells, histiocytes, flattened, transitional, renal tubules (small round), fat-containing cells, inclusion cells, multinucleated giant cells, epithelial cells such as atypical cells, hyaline, granular, and waxy cells. , red blood cells, white blood cells, blood, epithelium,
Other particles such as fat, casts such as casts, calcium oxalate, magnesium ammonium phosphate, calcium phosphate, calcium carbonate, ammonium urate, uric acid, crystals such as bilirubin, bacteria, yeast-like fungi, fat globules, amorphous salts, etc. be.

【0021】マーカー粒子としては動物、植物等の細胞
、微生物等の菌体、ラテックス粒子、マイクロカプセル
、デンプン粒子、ゼラチン粒子等を使用することができ
る。
[0021] As marker particles, cells of animals, plants, etc., cells of microorganisms, latex particles, microcapsules, starch particles, gelatin particles, etc. can be used.

【0022】前記のマーカー粒子は粒子径を1〜20μ
m好ましくは粒子径2〜10μmとすると、目視又は自
動セルカウンター等の自動粒子カウンターによる計数に
適し、比重を1.040以上好ましくは1.06〜1.
20とすると、尿中に添加して遠心分離により回収する
際に尿中の目的粒子と同様の回収率となる。
[0022] The marker particles have a particle size of 1 to 20μ.
If the particle diameter is preferably 2 to 10 μm, it is suitable for counting visually or by an automatic particle counter such as an automatic cell counter, and the specific gravity is 1.040 or more, preferably 1.06 to 1.0 μm.
When the particle size is 20, the recovery rate is the same as that of the target particles in urine when added to urine and recovered by centrifugation.

【0023】又マーカー粒子の色調は目的粒子の色調と
異なるものを選択すると、識別、計数が容易となる。マ
ーカー粒子の色調としては、検査施設により目的粒子を
スターンハイマー法、スターンハイマー=マルビン法等
により染色することもあるため、これらにより染色され
た目的粒子の色調とも異なる色調が好ましく、検鏡下に
黒色、褐色、緑色、金色等の赤、紫、青系統以外に観察
される色調とするとよい。具体的には、固定染色血球、
染色細胞、固定染色細胞、染色菌体、固定染色菌体、着
色ラテックス粒子、着色マイクロカプセル、着色デンプ
ン粒子、着色ゼラチン粒子等があげられる。
Further, if the color tone of the marker particles is selected to be different from the color tone of the target particles, identification and counting will be facilitated. As for the color tone of the marker particles, since target particles may be dyed by the Sternheimer method, Sternheimer-Marvin method, etc. depending on the testing facility, it is preferable to use a color tone that is different from the color tone of the target particles dyed by these methods. It is preferable to use colors observed other than red, purple, and blue, such as black, brown, green, and gold. Specifically, fixed stained blood cells,
Examples include stained cells, fixed stained cells, stained bacterial cells, fixed stained bacterial cells, colored latex particles, colored microcapsules, colored starch particles, and colored gelatin particles.

【0024】以上のマーカー粒子は尿の比重1.003
〜1.030に比べて若干比重が大きいため、長時間静
置しておくと沈降することもあるので、浮遊液の比重を
マーカー粒子の比重と同等以上とするとよい。浮遊液の
比重を調整するためには、一般的に使用されている緩衝
液を高濃度に使用してもよく、無機、有機の塩類、サッ
カロース、ラクトース、マンニット、ソルビット等の糖
類を加えてもよく、更にはプロピレングリコール(比重
1.036〜1.040)、ジメチルスルホキシド(比
重1.100〜1.105)、ジエチレングリコール(
比重1.113〜1.123)、エチレングリコール(
比重1.114〜1.117)、グリセリン(比重1.
260以上)等の有機溶媒を使用することもできる。す
なわち、尿沈渣中の目的粒子の性状及び遠心上清の尿検
査に影響を与えない限り、各種の物質を併用して比重調
整することができる。又、非イオン性界面活性剤を添加
することによりマーカー粒子の分散性を高めることもで
きる。
The above marker particles have a specific gravity of urine of 1.003.
Since the specific gravity is slightly higher than that of ~1.030, it may settle if left standing for a long time, so the specific gravity of the suspended liquid is preferably equal to or higher than the specific gravity of the marker particles. To adjust the specific gravity of the suspension, commonly used buffers may be used at high concentrations, and inorganic or organic salts, sugars such as saccharose, lactose, mannitol, sorbitol, etc. may be added. Furthermore, propylene glycol (specific gravity 1.036-1.040), dimethyl sulfoxide (specific gravity 1.100-1.105), diethylene glycol (
specific gravity 1.113-1.123), ethylene glycol (
specific gravity 1.114-1.117), glycerin (specific gravity 1.114-1.117), glycerin (specific gravity 1.114-1.117),
260 or higher) can also be used. That is, as long as it does not affect the properties of the target particles in the urine sediment or the urinalysis of the centrifuged supernatant, various substances can be used in combination to adjust the specific gravity. Furthermore, the dispersibility of marker particles can be improved by adding a nonionic surfactant.

【0025】マーカー粒子の製法の発明は、固定赤血球
とpH8〜10の緩衝液中に3,3´ージアミノベンチ
ジン、過酸化水素水及び界面活性剤を含む反応液とを混
合し、一定時間後洗浄することを特徴とするものである
The invention of the method for producing marker particles involves mixing fixed red blood cells with a reaction solution containing 3,3'-diaminobenzidine, hydrogen peroxide, and a surfactant in a buffer solution with a pH of 8 to 10, and then It is characterized by post-cleaning.

【0026】赤血球としてはヒトの他ウサギ、ウシ、ブ
タ、ヒツジ等の動物の赤血球を使用することができ、こ
れらの赤血球の固定はグルタルアルデヒド、ホルマリン
等により行うことができる。
As the red blood cells, red blood cells of animals such as rabbits, cows, pigs, and sheep, as well as humans, can be used, and these red blood cells can be fixed with glutaraldehyde, formalin, or the like.

【0027】pH8〜10の緩衝液の緩衝剤は、pH8
〜10の間に緩衝力のある種々の緩衝剤を使用すること
ができ、トリス−塩酸系、グリシン−NaOH系、ホウ
酸系等を使用することができる。
[0027] The buffer of pH 8 to 10 is pH 8 to 10.
Various buffering agents having a buffering power between 10 and 10 can be used, such as Tris-hydrochloric acid, glycine-NaOH, boric acid, and the like.

【0028】緩衝液中には3,3´ージアミノベンチジ
ン、過酸化水素水を加えるが、これらの他に非イオン性
界面活性剤を添加することができる。
[0028] 3,3'-diaminobenzidine and hydrogen peroxide are added to the buffer solution, but in addition to these, a nonionic surfactant can be added.

【0029】前記マーカー粒子の添加濃度は、少なすぎ
るとマーカー粒子のC.V.値が大きくなりすぎ、又多
すぎると計数に時間がかかるので、尿1μl当り5〜5
00個の範囲が適当である。この範囲であればマーカー
粒子の計数に要する時間は短くて済み、全体の操作時間
に大きな変動はなく、多数の検体処理においても支障と
ならない。
If the concentration of the marker particles added is too low, the C.I. V. If the value becomes too large, and if it is too large, it will take time to count, so 5 to 5
A range of 00 is appropriate. Within this range, the time required for counting marker particles is short, there is no large variation in the overall operation time, and there is no problem in processing a large number of specimens.

【0030】[0030]

【作用】マーカー粒子を尿中に5〜500個/μl例え
ば50個/μlの濃度に加えて遠心分離すると、尿中の
80〜90%の目的粒子及びマーカー粒子が沈降回収さ
れる。デカントにより上清を吸引除去し振盪により尿沈
渣を均一にした後たたきつけ法によりスライドグラスに
一滴(約15μl)採取し、カバーグラスをかけて検鏡
し、目的粒子及びマーカー粒子を1視野毎に計数し、複
数視野計数して目的粒子及びマーカー粒子を夫々平均す
る。
[Operation] When marker particles are added to urine at a concentration of 5 to 500 particles/μl, for example, 50 particles/μl, and centrifuged, 80 to 90% of the target particles and marker particles in the urine are sedimented and recovered. After removing the supernatant by decanting and homogenizing the urine sediment by shaking, collect one drop (approximately 15 μl) onto a slide glass using the knocking method, cover with a cover glass, and examine under a microscope to detect target particles and marker particles in each field of view. The target particles and marker particles are counted and averaged from multiple fields of view, respectively.

【0031】マーカー粒子の回収率を100%とすると
、理論的回収マーカー粒子数は1視野当り18.4個(
日本臨床検査技師会推奨法:尿10ml,1500r.
p.m.、5分、上清吸引除去、尿沈渣量200μl、
尿沈渣採取量15μl)であり、平均マーカー粒子数が
18.4個であれば回収率は100%である。例えば、
尿沈渣量が200μlを超えるような場合、濃縮率が5
0倍以下となり、平均マーカー粒子数は18.4個/H
PF以下となり、回収率は100%以下ということにな
るが、目的粒子の回収率も同一であるので、式1により
補正すれば、理論的回収粒子数を基準として補正される
。 又、尿沈渣量が200μlよりも少ない場合、デカント
では濃縮率が50倍以上となり、平均マーカー粒子数は
18.4個/HPF以上となり、回収率が100%以上
ということになるが、目的粒子の回収率も同一であるの
で式1により補正すれば、同様に理論的回収粒子数を基
準として補正される。
[0031] Assuming that the recovery rate of marker particles is 100%, the theoretical number of recovered marker particles is 18.4 per field of view (
Recommended method by the Japanese Society of Clinical Laboratory Technologists: 10ml of urine, 1500r.
p. m. , 5 minutes, suction removal of supernatant, urine sediment volume 200μl,
If the amount of urine sediment collected is 15 μl) and the average number of marker particles is 18.4, the recovery rate is 100%. for example,
If the amount of urine sediment exceeds 200 μl, the concentration rate is 5.
The average number of marker particles is 18.4/h.
PF or less, and the recovery rate is 100% or less, but since the recovery rate of the target particles is also the same, if it is corrected using Equation 1, it will be corrected based on the theoretical number of recovered particles. In addition, when the amount of urine sediment is less than 200 μl, the concentration rate is more than 50 times by decantation, the average number of marker particles is more than 18.4/HPF, and the recovery rate is more than 100%. Since the recovery rate of is also the same, if it is corrected using Equation 1, it will be similarly corrected based on the theoretical number of recovered particles.

【0032】これにより、尿検体の個体差と検査方法、
検査機器、検査担当者等の検査施設間差とが是正される
と共に再現性も向上し、1視野当りの平均目的粒子数が
理論回収粒子数を基準として補正され、標準化される。
[0032] As a result, individual differences in urine samples and testing methods,
Differences between inspection facilities such as inspection equipment and inspection personnel are corrected, and reproducibility is improved, and the average number of target particles per field of view is corrected and standardized based on the theoretical number of recovered particles.

【0033】又、各検査施設において実験により回収マ
ーカー粒子数の平均値を予め求めておくことにより、各
検査施設における従来の平均的回収粒子数を補正の基準
とすることができるため、式2により各検査施設におけ
る検査結果の判断基準を変更することなく、尿検体の個
体差が是正され、再現性等の測定精度が向上する。
[0033] Furthermore, by determining the average number of recovered marker particles in advance through experiments at each testing facility, the conventional average number of recovered marker particles at each testing facility can be used as the standard for correction. This will correct individual differences in urine samples and improve measurement accuracy such as reproducibility, without changing the criteria for determining test results at each testing facility.

【0034】更に、例えばマーカー粒子を尿検体中に5
0個/μlの濃度に加えておいた場合、複数視野におけ
る目的粒子とマーカー粒子の比率に50を乗ずることに
より、尿検体中の目的粒子の数を濃度表示することがで
き、しかも尿検体の個体差及び検査施設間差が是正され
ることから直接法にも対応できる。
Furthermore, for example, marker particles may be added to the urine sample at 5
When added to the concentration of 0 particles/μl, by multiplying the ratio of target particles to marker particles in multiple fields of view by 50, the number of target particles in the urine sample can be expressed as a concentration, and the concentration of the target particles in the urine sample can be displayed. Since individual differences and differences between testing facilities are corrected, it can also be used with the direct method.

【0035】更に又、尿にマーカー粒子を加えて遠心分
離し、得られた尿沈渣中の目的粒子及びマーカー粒子を
計数し、マーカー粒子に対する目的粒子の比率により尿
検体をランク分けすると、尿沈渣の検査を更に合理的に
且つ迅速化することができる。すなわち、近年は尿沈渣
中の各目的粒子の数を連続的数値で表現するよりも、目
的粒子に応じてその数に適当な区間を設定し、尿検体中
の目的粒子数をランク分けして検査成績の判断を容易に
すると共に検査を合理化する傾向にあり、特に検査成績
をコンピューターを用いてオンラインで報告するシステ
ムにおいてはランク分けする場合が多い。
Furthermore, when marker particles are added to urine and centrifuged, target particles and marker particles in the obtained urine sediment are counted, and the urine sample is ranked according to the ratio of target particles to marker particles, the urine sediment inspection can be made more rational and faster. In other words, in recent years, rather than expressing the number of each target particle in urine sediment as a continuous numerical value, appropriate intervals have been set for the number depending on the target particle, and the number of target particles in the urine sample has been ranked. There is a tendency to make it easier to judge test results and to streamline tests, and in particular systems that report test results online using a computer often rank them.

【0036】加えるマーカー粒子としては粒子径が1〜
20μmの範囲であれば検鏡時に認識が容易で計数可能
であり目的粒子と大きさを異にすれば識別が更に容易と
なると共に自動粒子カウンターによる計数も可能となる
。マーカー粒子の、比重が1.04以上であれば遠心分
離により回収可能であり、1.06〜1.20の範囲で
あれば遠心分離の際尿検体中の目的粒子と挙動を共にす
るので回収率がほぼ同じになる。又、マーカー粒子が目
的粒子と検鏡下の色調を異にしていると、マーカー粒子
との識別が更に容易となる。更に、マーカー粒子の比重
と同等以上の液体にマーカー粒子を浮遊することにより
、マーカー粒子の長期保存による沈降が防止され、添加
前の浮遊均一化が容易となり、直ちに使用でき、尿検体
への分散性も良好となる。
[0036] The marker particles to be added have a particle size of 1 to 1.
If the particle size is in the range of 20 μm, it is easy to recognize and count during microscopy, and if the particle size is different from the target particle, identification becomes even easier and counting by an automatic particle counter becomes possible. If the specific gravity of marker particles is 1.04 or more, it can be recovered by centrifugation, and if it is in the range of 1.06 to 1.20, it can be recovered because it behaves the same as the target particles in the urine sample during centrifugation. rates will be approximately the same. Further, if the marker particles have a different color tone under a microscope from the target particles, it becomes easier to distinguish them from the marker particles. Furthermore, by suspending the marker particles in a liquid with a specific gravity equal to or higher than that of the marker particles, sedimentation due to long-term storage of the marker particles is prevented, and suspension homogenization before addition is facilitated, allowing for immediate use and dispersion in urine samples. The properties are also improved.

【0037】[0037]

【実施例】実施例1 平均粒子径5μm、比重1.100のラテックス粒子を
緑色に着色したマーカー粒子を、10000個/μlに
調整し、尿10mlに対し50μlを添加すると、尿1
μl当りのマーカー粒子は50個となる。1500r.
p.m.で5分間遠心分離し、デカントにより上清を除
去し、尿沈渣を均一に懸濁した後たたきつけ法によりス
ライドグラス上に一滴(約15μl)とり、18×18
mmのカバーグラスをかけて400倍で検鏡し、目的粒
子である赤血球とマーカー粒子であるラテックス粒子を
夫々計数し、複数視野の平均値を夫々算出した。
[Example] Example 1 Marker particles made by coloring green latex particles with an average particle diameter of 5 μm and a specific gravity of 1.100 were adjusted to 10,000 particles/μl, and 50 μl was added to 10 ml of urine.
The number of marker particles per μl is 50. 1500r.
p. m. After centrifuging for 5 minutes at
The specimen was covered with a 3.0 mm cover glass and examined under a microscope at a magnification of 400 times, and the target particles (erythrocytes) and marker particles (latex particles) were counted, and the average values of multiple fields of view were calculated.

【0038】10視野の平均赤血球数は15.2個/1
視野(HPF)であり、平均マーカー粒子数は14.5
個/HPFであった。式1により補正した検体尿中の赤
血球数は、日本臨床検査技師会法による理論的回収マー
カー粒子数を18.4個/HPFとすると、19.3個
/HPFとなった。
[0038] The average number of red blood cells in 10 visual fields is 15.2/1
field of view (HPF), and the average number of marker particles is 14.5.
number/HPF. The number of red blood cells in the sample urine corrected by Equation 1 was 19.3 particles/HPF, assuming that the theoretical number of recovered marker particles according to the method of the Japanese Society of Clinical Laboratory Technicians was 18.4 particles/HPF.

【0039】実施例2 平均粒子径2μl、比重1.080のマイクロカプセル
を用いて前記実施例1と同様に操作したところ、平均白
血球数は1視野当り14.3個で、平均マーカー粒子数
は12.3個であった。
Example 2 The same procedure as in Example 1 was carried out using microcapsules with an average particle diameter of 2 μl and a specific gravity of 1.080. The average number of white blood cells was 14.3 per field of view, and the average number of marker particles was There were 12.3 pieces.

【0040】予め10例の尿検体を用いて同様に操作し
て得られた1視野ごとの平均回収マーカー粒子数は11
.6個であったので、式2により補正した尿検体中の白
血球数は13.5個/HPFとなった。
[0040] The average number of recovered marker particles per field of view obtained by performing the same procedure using 10 urine samples was 11.
.. Since the number of white blood cells was 6, the number of white blood cells in the urine sample corrected by Equation 2 was 13.5 cells/HPF.

【0041】実施例3 平均粒子径8μm、比重1.110のラッテクス粒子を
黒色に着色したマーカー粒子を用い、尿1μl当りのマ
ーカー粒子数を40個として、前記実施例1と同様に操
作したところ、平均赤血球数は27.8個/HPF、平
均マーカー粒子数は19.3個/HPFであった。式3
により補正した尿検体中の赤血球数は1μl当り57.
6個となった。
Example 3 The same procedure as in Example 1 was carried out using marker particles made of latex particles colored black with an average particle diameter of 8 μm and a specific gravity of 1.110, and the number of marker particles per 1 μl of urine was 40. The average number of red blood cells was 27.8/HPF, and the average number of marker particles was 19.3/HPF. Formula 3
The number of red blood cells in the urine sample corrected by 57.
There were 6 pieces.

【0042】実施例4 前記実施例1と同様に操作し、赤血球数とマーカー粒子
の平均比率を計算したところ、15.2:14.5であ
り、赤血球数はマーカー粒子数の1.05倍であった。 予め、1視野当りの理論的回収マーカー粒子数を18.
4個としてランク分けすると、1視野当りの赤血球の数
が1〜5個の場合、マーカー粒子に対する赤血球の比率
は、0.054〜0.272であり、同様に赤血球数が
6〜10個の場合0.326〜0.543であり、11
〜 20個の場合0.611〜1.087であり、21
〜50個の場合1.141〜2.717であり、51〜
100個の場合2.771〜5.435であり、101
個以上の場合5.489以上となる。従って、前記尿検
体は赤血球数比率が1.05であるので、赤血球数11
〜20個/HPFの範囲にランクされた。
Example 4 The average ratio of the number of red blood cells to the marker particles was calculated in the same manner as in Example 1, and the result was 15.2:14.5, and the number of red blood cells was 1.05 times the number of marker particles. Met. In advance, the theoretical number of collected marker particles per field of view was determined to be 18.
When ranked as 4 red blood cells, when the number of red blood cells per field is 1 to 5, the ratio of red blood cells to marker particles is 0.054 to 0.272, and similarly when the number of red blood cells is 6 to 10, case is 0.326 to 0.543, and 11
~ In the case of 20 pieces, it is 0.611 ~ 1.087, and 21
In the case of ~50 pieces, it is 1.141 ~ 2.717, and 51 ~
In the case of 100 pieces, it is 2.771 to 5.435, and 101
If the number is 5.489 or more, the value is 5.489 or more. Therefore, since the urine sample has a red blood cell count ratio of 1.05, the red blood cell count is 11.
It was ranked in the range of ~20 pieces/HPF.

【0043】実施例5 ヒト赤血球をグルタルアルデヒドで固定し、pH9のト
リス塩酸緩衝液に浮遊する。pH9のトリス塩酸緩衝液
50mlに3,3´ージアミノベンチジンを250mg
、3%過酸化水素水を1.5ml、及びツイーン80を
1.0mlを加えて反応液とする。該反応液と前記固定
赤血球とを等量混合し10分後PBSにて洗浄し、防腐
剤を加えたPBSに10000個/μlに調整、浮遊し
て冷蔵保存した。
Example 5 Human red blood cells are fixed with glutaraldehyde and suspended in a pH 9 Tris-HCl buffer. 250 mg of 3,3'-diaminobenzidine in 50 ml of pH 9 Tris-HCl buffer
, 1.5 ml of 3% hydrogen peroxide solution, and 1.0 ml of Tween 80 were added to prepare a reaction solution. The reaction solution and the fixed red blood cells were mixed in equal amounts, washed with PBS after 10 minutes, adjusted to 10,000 cells/μl in PBS containing a preservative, suspended, and stored refrigerated.

【0044】実施例6 プラスチック製標線付きスピッツ管に尿を10ml採取
し、実施例5で調製した固定染色血球を50μl添加し
、尿1μl当り50個の濃度とした。1500r.p.
m.5分間遠心分離し、上清をアスピレーターで吸引除
去し、沈渣量を200μlとし、マイクロピペットで均
一に混和後スライドグラス上に15μl採取し、カバー
グラスをかけて赤血球及び固定染色血球を計算し、10
視野を平均した。以上の操作を10回同時に繰り返した
ところ、平均赤血球数は12.3個/HPFでありC.
V.は8.5%であった。又、平均固定染色血球数は1
1.2個/HPFでありC.V.は8.3%であった。 固定染色血球の理論回収値を18.4個/HPFとして
式1により補正すると、尿検体中の赤血球数は20.2
個/HPFとなった。
Example 6 10 ml of urine was collected into a plastic Spitz tube with marked lines, and 50 μl of the fixed and stained blood cells prepared in Example 5 was added to give a concentration of 50 cells per 1 μl of urine. 1500r. p.
m. Centrifuge for 5 minutes, remove the supernatant with an aspirator, make the sediment volume 200 μl, mix uniformly with a micropipette, collect 15 μl onto a slide glass, cover with a cover glass, and count red blood cells and fixed stained blood cells. 10
The visual field was averaged. When the above operation was repeated 10 times at the same time, the average number of red blood cells was 12.3/HPF and C.
V. was 8.5%. In addition, the average number of fixed and stained blood cells was 1
1.2 pieces/HPF and C. V. was 8.3%. If the theoretical recovery value of fixed stained blood cells is 18.4 cells/HPF and corrected by formula 1, the number of red blood cells in the urine sample is 20.2.
pcs/HPF.

【0045】実施例7 尿検体30例を用いて実施例6と同様の操作により、各
尿検体の1視野当りの平均赤血球数及び平均固定染色血
球数を求めた。固定染色血球の30例の平均値は13.
3個/HPFで、C.V.は22.2%であった。実験
的に得られた平均値13.3個/HPFを用いて式2に
より、各尿検体の赤血球数を補正した。
Example 7 Using 30 urine specimens, the average number of red blood cells and the average number of fixed stained blood cells per field of view were determined for each urine specimen in the same manner as in Example 6. The average value of 30 cases of fixed and stained blood cells was 13.
3 pieces/HPF, C. V. was 22.2%. The number of red blood cells in each urine sample was corrected using Equation 2 using the experimentally obtained average value of 13.3 cells/HPF.

【0046】実施例8 実施例6において、スピッツ管をガラス製とし、上清の
除去をデカントとし、尿沈渣の採取をたたきつけ法で行
った。1視野当りの平均赤血球数の10回平均値は38
.8個で、C.V.は24.3%、又固定染色血球は平
均値39.5個、C.V.は22.1%であった。理論
回収値を18.4個/HPFとして式1により補正した
ところ、平均赤血球数は18.1個/HPFとなった。
Example 8 In Example 6, the Spitz tube was made of glass, the supernatant was removed using a decant, and the urine sediment was collected by the tapping method. The average number of red blood cells per field of view for 10 times is 38.
.. With 8 pieces, C. V. was 24.3%, and the average number of fixed and stained blood cells was 39.5. V. was 22.1%. When the theoretical recovery value was set as 18.4 cells/HPF and corrected using Formula 1, the average number of red blood cells was 18.1 cells/HPF.

【0047】実施例9 実施例7で使用した尿検体30例を用いて、実施例8と
同様の操作により、各尿検体の1視野当りの平均赤血球
数及び平均固定染色血球数を求めた。固定染色血球の3
0例の平均値は38.5個/HPFで、C.V.は44
.8%であった。実験的に得られた平均値38.5個/
HPFを用いて、式2により各尿検体の赤血球数を補正
したところ、実施例7で得られた30例の尿検体の赤血
球数と近似した補正値が夫々得られた。
Example 9 Using the 30 urine samples used in Example 7, the average number of red blood cells and the average number of fixed stained blood cells per field of view of each urine sample were determined by the same procedure as in Example 8. Fixed stained blood cells 3
The average value of 0 cases was 38.5 pieces/HPF, and C. V. is 44
.. It was 8%. Experimentally obtained average value: 38.5 pieces/
When the red blood cell count of each urine sample was corrected using HPF according to Equation 2, corrected values similar to the red blood cell counts of the 30 urine samples obtained in Example 7 were obtained.

【0048】実施例10 実施例8において、尿沈渣の採取をスポイトで15μl
採取することにより行った。平均赤血球数の10回平均
値は35.2個/HPFでC.V.は11.5%、又固
定染色血球は平均値34.0個/HPFでC.V.は1
0.6%であった。理論回収値を18.4個/HPFと
して式1により補正したところ、平均赤血球数は19.
0個/HPFとなった。
Example 10 In Example 8, 15 μl of urine sediment was collected using a dropper.
This was done by sampling. The 10-time average value of the average red blood cell count was 35.2 cells/HPF, which was C. V. C. was 11.5%, and the average value of fixed and stained blood cells was 34.0 cells/HPF. V. is 1
It was 0.6%. When the theoretical recovery value was set as 18.4 cells/HPF and corrected using equation 1, the average red blood cell count was 19.
It became 0 pieces/HPF.

【0049】実施例11 実施例7で使用した尿検体30例を用いて、実施例10
と同様の操作により、各尿検体の1視野当りの平均赤血
球数及び平均固定染色血球数を求めた。固定染色血球の
30例の平均値は26.2個/HPFで、C.V.は3
9.4%であった。実験的に得られた平均値26.2個
/HPFを用いて、式2により各尿検体の赤血球数を補
正したところ、実施例7及び9で得られた30例の尿検
体の赤血球数と近似した補正値が夫々得られた。
Example 11 Using the 30 urine samples used in Example 7, Example 10
The average number of red blood cells and the average number of fixed stained blood cells per field of view for each urine specimen were determined by the same procedure as above. The average value of fixed stained blood cells in 30 cases was 26.2 cells/HPF, and C. V. is 3
It was 9.4%. Using the experimentally obtained average value of 26.2 cells/HPF, the number of red blood cells in each urine sample was corrected using formula 2, and the number of red blood cells in the 30 urine samples obtained in Examples 7 and 9 was Approximate correction values were obtained respectively.

【0050】実施例12 採尿カップに採取された尿の液量を採尿カップの目盛り
を利用して読みとり、尿10ml当り、ヨードデンプン
反応により着色したデンプン粒子(18500個/μl
)を10μl加え、(18.5個/μl尿)、採尿カッ
プを揺り動かすと青色のデンプン粒子が均一に浮遊され
内容物が均一に混和されたことが確認できた。この尿を
スピッツ管に10ml採取し、実施例1と同様に操作し
た。
Example 12 The amount of urine collected in the urine collection cup was read using the scale of the urine collection cup, and starch particles colored by the iodostarch reaction (18,500 particles/μl) were measured per 10ml of urine.
) was added (18.5 particles/μl urine), and when the urine collection cup was shaken, it was confirmed that the blue starch particles were evenly suspended and the contents were mixed uniformly. 10 ml of this urine was collected into a Spitz tube and operated in the same manner as in Example 1.

【0051】10視野の着色デンプン粒子は5個/HP
F前後であったので尿の均一化が裏付けられた。又平均
赤血球数は20.4個/HPF、平均ラテックス粒子数
は13.7個であった。理論的回収ラテックス数を18
.4個/HPFとして、式1により補正すると赤血球数
は27.4個/HPFとなった。
[0051] 5 colored starch particles/HP in 10 visual fields
Since it was around F, it was confirmed that the urine was homogenized. The average number of red blood cells was 20.4/HPF, and the average number of latex particles was 13.7. The theoretical number of recovered latex is 18.
.. Assuming 4 cells/HPF, the number of red blood cells was corrected using equation 1 to be 27.4 cells/HPF.

【0052】本実施例によれば、大きさ及び又は色調の
異なる二種類のマーカー粒子を採尿カップとスピッツ管
に加えることにより、尿採取時の成分の均一化が容易且
つ確実に確認できると共に目的粒子の補正も行えるので
、尿検体の個体差が改善されるばかりでなく、再現性が
向上し検査成績の質が著しく高められた。
According to this example, by adding two types of marker particles with different sizes and/or colors to the urine collection cup and Spitz tube, it is possible to easily and reliably confirm the uniformity of the components during urine collection, and also to achieve the purpose. Particle correction can also be performed, which not only improves individual differences in urine samples, but also improves reproducibility and significantly improves the quality of test results.

【0053】実施例13 平均粒子径3μm、比重1.050のラテックス粒子を
10000個/μlに調整し、尿10ml当り50μl
を添加してよく混和した。これを、直接に自動粒子カウ
ンターにより、粒子径7μmの赤血球と3μmのマーカ
ー粒子とを区別して計数した。マーカー粒子は表示濃度
が50個/μlであるのに対し、測定値が49個/μl
であったので、尿の混和が充分行われたことが確認され
た。
Example 13 Latex particles with an average particle diameter of 3 μm and a specific gravity of 1.050 were adjusted to 10,000 particles/μl, and 50 μl was added per 10 ml of urine.
was added and mixed well. This was directly counted using an automatic particle counter, distinguishing between red blood cells with a particle size of 7 μm and marker particles with a particle size of 3 μm. The displayed concentration of marker particles is 50 particles/μl, but the measured value is 49 particles/μl.
Therefore, it was confirmed that the urine was sufficiently mixed.

【0054】[0054]

【発明の効果】以上述べたように本発明によれば下記の
種々の優れた効果が得られる。
[Effects of the Invention] As described above, according to the present invention, the following various excellent effects can be obtained.

【0055】1.本発明の方法によれば尿沈渣の検査成
績を測定者間差、施設間差ばかりでなく尿検体の個体差
も是正することができ、精度管理に有用である。
1. According to the method of the present invention, it is possible to correct not only inter-measurer differences and inter-facility differences in urine sediment test results, but also individual differences in urine samples, and is useful for quality control.

【0056】2.マーカー粒子の1視野当りの理論的回
収値を基準に、式1により目的粒子数を補正すれば、日
本臨床検査技師会法に合致した検査成績が得られ、検査
施設内はもちろん検査施設間の標準化が全国的規模で可
能になる。
2. If the target particle number is corrected using Equation 1 based on the theoretical recovery value of marker particles per field of view, test results that comply with the Japanese Society of Clinical Laboratory Technicians method can be obtained, and it can be used not only within a testing facility but also between testing facilities. Standardization becomes possible on a national scale.

【0057】3.マーカー粒子の1視野当りの実験的回
収平均値を基準に、式2により目的粒子数を補正すれば
、各検査施設における従来の判断基準を変更することな
く、尿検体の個体差を是正することができる。
3. By correcting the number of target particles using Equation 2 based on the experimentally recovered average value of marker particles per field of view, individual differences in urine samples can be corrected without changing the conventional judgment criteria at each testing facility. Can be done.

【0058】4.1視野当りの平均目的粒子数と平均マ
ーカー粒子とを求め式3により補正すれば、目的粒子の
尿中の濃度(個/μl尿)が得られ、尿中の目的粒子数
を直接濃度表示することができる。更に、式2による補
正と併用することにより各検査施設における従来の判断
基準を変更することなく、濃度表示により検査施設間の
標準化が可能になる。
4. By calculating the average number of target particles and the average marker particles per field of view and correcting them using equation 3, the concentration of target particles in urine (particles/μl urine) can be obtained, and the number of target particles in urine can be obtained. The concentration can be displayed directly. Furthermore, when used together with the correction based on Equation 2, the concentration display allows standardization among testing facilities without changing the conventional judgment criteria of each testing facility.

【0059】5.1視野当りの平均目的粒子数と平均マ
ーカー粒子数との比率により、尿検体を目的粒子ごとに
ランク分けすることができるので、計数及び報告が容易
となり、合理化できる。
5. Urine specimens can be ranked for each target particle based on the ratio of the average number of target particles per field of view to the average number of marker particles, making counting and reporting easy and rational.

【0060】6.マーカー粒子の径を1〜20μm、比
重を1.04以上としたので、尿検体からの回収率が目
的粒子と略同一となり、検鏡の際にも容易に計数できる
6. Since the marker particles have a diameter of 1 to 20 μm and a specific gravity of 1.04 or more, the recovery rate from the urine specimen is approximately the same as that of the target particles, and they can be easily counted during microscopy.

【0061】7.マーカー粒子の径を目的粒子の径と異
ならせれば識別は更に容易となり、更にマーカー粒子と
目的粒子の色調を異ならせると識別、計数がより一層容
易となる。
7. If the diameter of the marker particles is different from that of the target particles, identification becomes easier, and if the color tones of the marker particles and the target particles are different, identification and counting become even easier.

【0062】8.赤血球を固定して、染色することによ
り、識別し易くしかも安定なマーカー粒子を得ることが
できる。
8. By fixing and staining red blood cells, marker particles that are easy to identify and are stable can be obtained.

【図面の簡単な説明】[Brief explanation of the drawing]

【図1】尿沈渣検査方法を示した説明図である。FIG. 1 is an explanatory diagram showing a urine sediment testing method.

【符号の説明】[Explanation of symbols]

1  採尿カップ 2  尿検体 3  スピッツ管 4  標線 5  遠心分離機 6  尿沈渣 9  顕微鏡 10  スポイト 1 Urine collection cup 2 Urine sample 3 Spitz tube 4 Marked line 5 Centrifugal separator 6 Urine sediment 9 Microscope 10 Dropper

Claims (19)

【特許請求の範囲】[Claims] 【請求項1】  尿にマーカー粒子を加えて遠心分離し
、得られる尿沈渣中の目的粒子及びマーカー粒子を計数
し、マーカー粒子の回収率により目的粒子の数を補正す
ることを特徴とする尿沈渣検査成績管理方法。
1. Urine characterized in that marker particles are added to urine and centrifuged, target particles and marker particles in the obtained urine sediment are counted, and the number of target particles is corrected based on the recovery rate of marker particles. Sediment test results management method.
【請求項2】  (計数された目的粒子の数)×(理論
的回収マーカー粒子数÷計数されたマーカー粒子の数)
…(式1)により補正する請求項1記載の尿沈渣検査成
績管理方法。
Claim 2: (Number of target particles counted) x (Theoretical number of recovered marker particles ÷ Number of marker particles counted)
The method for managing urinary sediment test results according to claim 1, wherein the correction is performed according to formula 1.
【請求項3】  (計数された目的粒子の数)×(実験
的回収マーカー粒子数÷計数されたマーカー粒子の数)
…(式2)により補正する請求項1記載の尿沈渣検査成
績管理方法。
Claim 3: (Number of target particles counted) x (Number of experimentally recovered marker particles ÷ Number of marker particles counted)
The method for managing urinary sediment test results according to claim 1, wherein the correction is performed according to formula 2.
【請求項4】  (計数された目的粒子の数÷計数され
たマーカー粒子の数)×(添加されたマーカー粒子の尿
中濃度)…(式3)により補正する請求項1記載の尿沈
渣検査成績管理方法。
4. The urinary sediment test according to claim 1, which is corrected by (the number of counted target particles ÷ the number of counted marker particles) x (urinary concentration of added marker particles) (Equation 3). How to manage grades.
【請求項5】  尿にマーカー粒子を加えて遠心分離し
、得られる尿沈渣中の目的粒子及びマーカー粒子を計数
し、マーカー粒子に対する目的粒子の比率により尿検体
をランク分けすることを特徴とする尿沈渣検査成績管理
方法。
[Claim 5] The method is characterized in that marker particles are added to urine and centrifuged, target particles and marker particles in the obtained urine sediment are counted, and the urine sample is ranked according to the ratio of target particles to marker particles. Method for managing urine sediment test results.
【請求項6】  マーカー粒子が粒子径1〜20μm、
比重1.040以上である請求項1、2、3、4又は5
記載の尿沈渣検査成績管理方法。
6. The marker particles have a particle size of 1 to 20 μm,
Claim 1, 2, 3, 4 or 5, wherein the specific gravity is 1.040 or more.
The urine sediment test results management method described.
【請求項7】  マーカー粒子が目的粒子と粒子径を異
にする請求項1、2、3、4又は5記載の尿沈渣検査成
績管理方法。
7. The method for managing urine sediment test results according to claim 1, 2, 3, 4, or 5, wherein the marker particles have a different particle size from the target particles.
【請求項8】  マーカー粒子が目的粒子と粒子径を異
にし、計数を自動粒子カウンターで行う請求項1、2、
3、4又は5記載の尿沈渣検査成績管理方法。
8. The marker particles have different particle diameters from the target particles, and counting is performed using an automatic particle counter.
The method for managing urine sediment test results according to 3, 4 or 5.
【請求項9】  マーカー粒子が細胞、菌体、ラテック
ス粒子、マイクロカプセル、デンプン粒子、ゼラチン粒
子、花粉である請求項1、2、3、4又は5記載の尿沈
渣検査成績管理方法。
9. The method for managing urine sediment test results according to claim 1, 2, 3, 4, or 5, wherein the marker particles are cells, bacterial cells, latex particles, microcapsules, starch particles, gelatin particles, or pollen.
【請求項10】  マーカー粒子が目的粒子と検鏡下の
色調を異にする請求項1、2、3、4又は5記載の尿沈
渣検査成績管理方法。
10. The method for managing urine sediment test results according to claim 1, 2, 3, 4, or 5, wherein the marker particles have a different color tone under a microscope than the target particles.
【請求項11】  マーカー粒子が固定染色血球、染色
細胞、固定染色細胞、染色菌体、固定染色菌体、着色ラ
テックス粒子、着色マイクロカプセル、着色デンプン粒
子、着色ゼラチン粒子である請求項1、2、3、4又は
5記載の尿沈渣検査成績管理方法。
11. Claims 1 and 2 wherein the marker particles are fixed stained blood cells, stained cells, fixed stained cells, stained bacterial cells, fixed stained bacterial cells, colored latex particles, colored microcapsules, colored starch particles, and colored gelatin particles. , 3, 4 or 5, the urine sediment test results management method.
【請求項12】  粒子径1〜20μm、比重1.04
0以上である尿沈渣検査成績管理用のマーカー粒子。
Claim 12: Particle size: 1 to 20 μm, specific gravity: 1.04
A marker particle for managing urine sediment test results whose value is 0 or more.
【請求項13】  マーカー粒子が尿沈渣中の目的粒子
と粒子径を異にする請求項12記載のマーカー粒子。
13. The marker particle according to claim 12, wherein the marker particle has a particle size different from that of the target particle in urine sediment.
【請求項14】  マーカー粒子が細胞、菌体、ラテッ
クス粒子、マイクロカプセル、デンプン粒子、ゼラチン
粒子である請求項12記載のマーカー粒子。
14. The marker particle according to claim 12, wherein the marker particle is a cell, a bacterial cell, a latex particle, a microcapsule, a starch particle, or a gelatin particle.
【請求項15】  マーカー粒子が目的粒子と検鏡下の
色調を異にする請求項12記載のマーカー粒子。
15. The marker particle according to claim 12, wherein the marker particle has a different color tone under a microscope than the target particle.
【請求項16】  マーカー粒子が固定染色血球、染色
細胞、固定染色細胞、染色菌体、固定染色菌体、着色ラ
テックス粒子、着色マイクロカプセル、着色デンプン粒
子、着色ゼラチン粒子である請求項15記載のマーカー
粒子。
16. The marker particles according to claim 15, wherein the marker particles are fixed stained blood cells, stained cells, fixed stained cells, stained bacterial cells, fixed stained bacterial cells, colored latex particles, colored microcapsules, colored starch particles, and colored gelatin particles. marker particles.
【請求項17】  マーカー粒子の比重と同等以上の比
重を有する液体に懸濁してなる請求項12記載のマーカ
ー粒子。
17. The marker particles according to claim 12, which are suspended in a liquid having a specific gravity equal to or higher than that of the marker particles.
【請求項18】  固定赤血球とpH8〜10の緩衝液
中に3,3´ージアミノベンチジン、過酸化水素水及び
界面活性剤を含む反応液とを混合し、一定時間後洗浄す
ることを特徴とする尿沈渣検査成績管理用マーカー粒子
の製法。
18. A method characterized in that fixed red blood cells are mixed with a reaction solution containing 3,3'-diaminobenzidine, hydrogen peroxide, and a surfactant in a buffer solution with a pH of 8 to 10, and washed after a certain period of time. A method for producing marker particles for managing urine sediment test results.
【請求項19】  グルタールアルデヒド固定赤血球と
pH9のトリス塩酸緩衝液中に3,3´ージアミノベン
チジン、過酸化水素水及び非イオン性界面活性剤を含む
反応液とを混合し、一定時間後洗浄する請求項18記載
の製法。
19. Glutaraldehyde-fixed red blood cells are mixed with a reaction solution containing 3,3'-diaminobenzidine, hydrogen peroxide, and a nonionic surfactant in a pH 9 Tris-HCl buffer, and the mixture is incubated for a certain period of time. 19. The method according to claim 18, further comprising post-washing.
JP3063837A 1991-03-06 1991-03-06 Urine sediment test result management method Expired - Fee Related JP2913219B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3063837A JP2913219B2 (en) 1991-03-06 1991-03-06 Urine sediment test result management method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3063837A JP2913219B2 (en) 1991-03-06 1991-03-06 Urine sediment test result management method

Publications (2)

Publication Number Publication Date
JPH04278460A true JPH04278460A (en) 1992-10-05
JP2913219B2 JP2913219B2 (en) 1999-06-28

Family

ID=13240864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3063837A Expired - Fee Related JP2913219B2 (en) 1991-03-06 1991-03-06 Urine sediment test result management method

Country Status (1)

Country Link
JP (1) JP2913219B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0774655A2 (en) 1995-11-17 1997-05-21 Toa Medical Electronics Co., Ltd. Standard fluid for flow cytometer
WO2015129863A1 (en) * 2014-02-28 2015-09-03 シスメックス株式会社 Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis
CN111175099A (en) * 2019-12-09 2020-05-19 湖北泰康医疗设备有限公司 Method for extracting and flaking humoral cells for bladder cancer examination

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520402A (en) * 1978-07-18 1980-02-13 Isao Inagaki Urine dregs counter
JPS5569052A (en) * 1978-11-21 1980-05-24 Omron Tateisi Electronics Co Urinary sediment sorting counter
JPS6179163A (en) * 1984-09-26 1986-04-22 Toa Medical Electronics Co Ltd Reagent for measuring blood cell
JPS61281967A (en) * 1985-06-07 1986-12-12 Terumo Corp Inspecting tube for urine sediment
JPS6283965U (en) * 1985-11-14 1987-05-28
JPS63171343A (en) * 1986-08-29 1988-07-15 ベクトン・ディッキンソン・アンド・カンパニー Reagent kit used for testing fluorescence analyzer
JPS63243879A (en) * 1987-03-31 1988-10-11 Nippon Koden Corp Standard solution for calibrating hemocytometer
JPS63317098A (en) * 1987-06-15 1988-12-26 アースレツクス・コーポレイシヨン Detection of bacteria in urine and treatment of diseases relating to rheumatoid arthritis, essential hypertensive disease and other bacteriuria
JPH01301166A (en) * 1988-05-30 1989-12-05 Japan Synthetic Rubber Co Ltd Standard liquid for calibrating blood cell counter
JPH04252957A (en) * 1990-08-07 1992-09-08 Becton Dickinson & Co One-step test for absolute count

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520402A (en) * 1978-07-18 1980-02-13 Isao Inagaki Urine dregs counter
JPS5569052A (en) * 1978-11-21 1980-05-24 Omron Tateisi Electronics Co Urinary sediment sorting counter
JPS6179163A (en) * 1984-09-26 1986-04-22 Toa Medical Electronics Co Ltd Reagent for measuring blood cell
JPS61281967A (en) * 1985-06-07 1986-12-12 Terumo Corp Inspecting tube for urine sediment
JPS6283965U (en) * 1985-11-14 1987-05-28
JPS63171343A (en) * 1986-08-29 1988-07-15 ベクトン・ディッキンソン・アンド・カンパニー Reagent kit used for testing fluorescence analyzer
JPS63177038A (en) * 1986-08-29 1988-07-21 ベクトン・ディッキンソン・アンド・カンパニー Particle stock item used for testing fluorometric analyzer
JPS63243879A (en) * 1987-03-31 1988-10-11 Nippon Koden Corp Standard solution for calibrating hemocytometer
JPS63317098A (en) * 1987-06-15 1988-12-26 アースレツクス・コーポレイシヨン Detection of bacteria in urine and treatment of diseases relating to rheumatoid arthritis, essential hypertensive disease and other bacteriuria
JPH01301166A (en) * 1988-05-30 1989-12-05 Japan Synthetic Rubber Co Ltd Standard liquid for calibrating blood cell counter
JPH04252957A (en) * 1990-08-07 1992-09-08 Becton Dickinson & Co One-step test for absolute count

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0774655A2 (en) 1995-11-17 1997-05-21 Toa Medical Electronics Co., Ltd. Standard fluid for flow cytometer
US5888823A (en) * 1995-11-17 1999-03-30 Toa Medical Electronics Co., Ltd. Standard fluid for flow cytometer
WO2015129863A1 (en) * 2014-02-28 2015-09-03 シスメックス株式会社 Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis
US10794809B2 (en) 2014-02-28 2020-10-06 Sysmex Corporation Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis
CN111175099A (en) * 2019-12-09 2020-05-19 湖北泰康医疗设备有限公司 Method for extracting and flaking humoral cells for bladder cancer examination

Also Published As

Publication number Publication date
JP2913219B2 (en) 1999-06-28

Similar Documents

Publication Publication Date Title
Hannemann-Pohl et al. Automation of urine sediment examination: a comparison of the Sysmex UF-100 automated flow cytometer with routine manual diagnosis (microscopy, test strips, and bacterial culture)
Horan et al. Fluorescent cell labeling for in vivo and in vitro cell tracking
US4615878A (en) Metachromatic dye sorption means for differential determination of sub-populations of lymphocytes
NZ571425A (en) Microfluidic chamber assembly for mastitis assay with wedge shaped chamber
JP3725553B2 (en) Reagent system and method for differentiating and identifying reticulocytes
JPH03266999A (en) Reagent for automatic flow sightmetry measurement of sub-population of at least one leukocyte from whole blood and measuring method using said reagent
LOHR Use of routine urinalysis in making a presumptive diagnosis of urinary tract infection in children
Koken et al. Determination of cut-off values for leucocytes and bacteria for urine flow cytometer (UF-100) in urinary tract infections
US5945340A (en) Reticulocyte assay control
Okada et al. Automated urinalysis: evaluation of the Sysmex UF-50
Kouri et al. ISLH recommended reference procedure for the enumeration of particles in urine
Dimech et al. Evaluation of an automated urinalysis system for testing urine chemistry, microscopy and culture
JP2001174456A (en) Device and method for subclassification of leukocyte
US6444471B1 (en) Reticulocyte containing complete blood control
JP2002005925A (en) Measuring method of crushed erythrocyte
JPH04278460A (en) Method for controlling examination result of urine sediment, control marker particle and preparation thereof
JPS6360862B2 (en)
CN115197322B (en) Antibody composition for detecting micro residual focus of chronic lymphocytic leukemia and application thereof
Ridley et al. Considerations for microscopic examination of urine
Gunawardena et al. Comparison of Automated and Manual Reticulocyte Count in a cohort of patient’s samples in Haematology Laboratory of Colombo South Teaching Hospital, Sri Lanka
Schumann et al. Comparing slide systems for microscopic urinalysis
Glass et al. Automated platelet counting
Caraballo et al. Semen Analysis
Gyamfi et al. Assessing Concordance of Results: A Comparative Study of the Manual and Automated Urinalysis Methods
CN111721950A (en) Stable formed component analysis coking liquid and preparation method thereof

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090416

Year of fee payment: 10

LAPS Cancellation because of no payment of annual fees